Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

被引：0
|
作者：
Cyrus DeSouza
Vivian Fonseca
机构：
[1] Cyrus DeSouza is at the University of Nebraska Medical Center,
[2] Omaha,undefined
[3] Nebraska,undefined
[4] USA and at Omaha Veteran Affairs Medical Center,undefined
[5] Omaha,undefined
[6] Nebraska,undefined
[7] USA.,undefined
[8] Vivian Fonseca is at Tulane University Health Sciences Center,undefined
[9] 1430 Tulane Avenue,undefined
[10] SL 53 New Orleans,undefined
[11] Los Angeles,undefined
[12] USA.,undefined
来源：
Nature Reviews Drug Discovery | 2009年 / 8卷 / 5期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cardiovascular disease associated with type 2 diabetes has become a major issue in the development of new diabetes therapies. DeSouza and Fonseca review the background to and implications of recent regulatory guidance for cardiovascular risk assessment of new antidiabetic agents, and discuss the potential beneficial cardiovascular effects of selected agents currently in development.
引用
收藏
页码：361 / 367
页数：6
相关论文
共 50 条
  • [1] OPINION Therapeutic targets to reduce cardiovascular disease in type 2 diabetes
    DeSouza, Cyrus
    Fonseca, Vivian
    NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (05) : 361 - 367
  • [2] ASSESSMENT OF THERAPEUTIC TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
    Grigorescu, E-D
    Lacatusu, C-M
    Onofriescu, A.
    Cazac, G. D.
    Ceasovschih, A.
    Dragoi, S-N
    Grigorescu, A-G
    Sorodoc, L.
    Mihai, B-M
    ATHEROSCLEROSIS, 2022, 355 : E200 - E200
  • [3] New targets to reduce cardiovascular disease in patients with diabetes
    Holt, RIG
    DIABETES OBESITY & METABOLISM, 2006, 8 (03): : 352 - 352
  • [4] Network analysis of circulating microRNAs reveals novel therapeutic targets in subjects with type 2 diabetes and cardiovascular disease
    Grieco, G. E.
    Besharat, Z. M.
    Mori, A.
    Trocchianesi, S.
    Farina, L.
    Petti, M.
    Alfano, C.
    Auddino, S.
    Bruttini, M.
    Po, A.
    Nesti, L.
    Natali, A.
    Sebastiani, G.
    Ferretti, E.
    Dotta, F.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S477 - S477
  • [5] Gut microbiome-derived secondary bile acids: therapeutic targets for reducing cardiovascular disease in type 2 diabetes?
    Johnson, Sarah A.
    Weir, Tiffany L.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2024, 119 (02): : 241 - 243
  • [6] Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus
    Zu, Guoxiu
    Sun, Keyun
    Li, Ling
    Zu, Xiuli
    Han, Tao
    Huang, Hailiang
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus
    Guoxiu Zu
    Keyun Sun
    Ling Li
    Xiuli Zu
    Tao Han
    Hailiang Huang
    Scientific Reports, 11
  • [8] SCREENING FOR TYPE 2 DIABETES SHOWN NOT TO REDUCE CARDIOVASCULAR DISEASE (CVD) OR DIABETES RELATED COMPLICATIONS
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2017, 19 (11): : 1640 - 1641
  • [9] Therapeutic targets to reduce cardiovascular disease in type 2 diabetes (Reprinted from Nature Reviews Drug Discovery, vol 8, pg 361-367, 2009)
    DeSouza, Cyrus
    Fonseca, Vivian
    NATURE REVIEWS DRUG DISCOVERY, 2010, : 5 - 11
  • [10] Therapeutic goals in diabetes type 2 (OFEDIA study): what is the impact of cardiovascular risk to the achievement of therapeutic targets
    Krempf, M.
    Huet, D.
    Dallongeville, J.
    Crisan, O.
    Sauvage, N.
    Bruckert, E.
    DIABETES & METABOLISM, 2012, 38 : A58 - A59
12345